21 / 49
Median PFS, months (95% CI)
18.9 (15.2, 21.4)
10.2 (9.6, 11.1)
1.0
Probability of progression-free survival
0.2
0.4
0.6
0.8
0.0
0
3
6
9
12
15
18
21
24
27
Time from randomisation (months)
279
277
262
239
233
197
210
152
178
107
139
78
71
37
26
10
4
2
0
0
No. at risk
Osimertinib
SoC
Osimertinib
SoC
HR 0.46
(95% CI 0.37, 0.57)
p<0.0001
# Do we know if EGFR mut pts
eventually will all develop T790M? Do
we know in advance which pt will
develop T790M?
# Can we only choose to treat patients
who eventually will develop T790M?
# Do patients who will not develop
T790M benefit from osimertinib first
line treatment?
Osimertinib for all patients in first line EGFR mut, OR sequence has sense in a subgroup of
patients?